No Data
Investors in Jafron BiomedicalLtd (SZSE:300529) Have Unfortunately Lost 44% Over the Last Five Years
Southwest Securities: The stable trend of hemodialysis treatment rates is expected to improve the concentration of domestic consumables through centralized procurement.
The time for domestic substitution of equipment is right; under the centralized procurement policy, leading enterprises with strong supply capabilities have a high selection rate, and the concentration of the Industry is expected to increase.
Jafron Biomedical (300529.SZ) issued a profit warning, expecting an annual net income of 0.8 billion yuan to 0.86 billion yuan, a year-on-year increase of 83% to 97%.
Jafron Biomedical (300529.SZ) disclosed the performance increase announcement for 2024, and the company expects to report a profit attributable to the listed company...
Jianfan Biotech: 2024 Annual Results Advance Announcement
Are Jafron Biomedical Co.,Ltd.'s (SZSE:300529) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Market Still Lacking Some Conviction On Jafron Biomedical Co.,Ltd. (SZSE:300529)
Jafron BiomedicalLtd's (SZSE:300529) Earnings Trajectory Could Turn Positive as the Stock Increases 7.1% This Past Week
